Pravastatin
Hmg Coa Reductase Inhibitors
- Drug class
- Hmg Coa Reductase Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 41
Overview
Plain-language summary, compiled from the cited regulatory records
Pravastatin is a medication belonging to the HMG-CoA reductase inhibitor drug class, commonly known as statins [1]. It is used as part of a comprehensive treatment plan for individuals with hypercholesterolemia who are at increased risk for atherosclerotic vascular disease [1].
This therapy is intended to be used alongside diet and other non-pharmacological measures when these interventions alone have not been sufficient to manage cholesterol levels [1]. Pravastatin is approved for use as an adjunct to diet in patients requiring lipid-altering therapy [1].
Pravastatin is available under various brand names [1]. There were no adverse event reports for this drug in the last 12 months [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 24 | May 29, 2026 |
| US United States | FDA | 11 | February 13, 2026 |
| CA Canada | Health Canada | 6 | January 5, 2026 |
GBUnited Kingdom· MHRA
24 products
Uses
g. exercise, weight reduction) is inadequate. 1). 1). Post transplantation Reduction of post transplantation hyperlipidaemia in patients receiving immunosuppressive therapy following solid organ transplantation. 1).
How to take
USUnited States· FDA
11 products
Uses
1 INDICATIONS AND USAGE Pravastatin sodium tablets are indicated: To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).
To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.
As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
As an adjunct to diet for the treatment of adults with:
Primary dysbetalipoproteinemia. Hypertriglyceridemia.
CACanada· Health Canada
6 products
6 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Pravastatin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 514. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL163630306 · revised May 29, 2026
- [2]FDA DailyMed · 0c4b59f1-92a8-44… · revised February 13, 2026 [PDF]
- [3]Health Canada (DPD) · 02356546 · revised January 5, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.